Pliant Therapeutics, Inc. (PLRX)
1.01
+0.01
(+1.00%)
USD |
NASDAQ |
Oct 09, 14:28
Pliant Therapeutics Enterprise Value : -67.44M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | -67.44M |
| October 07, 2026 | -68.06M |
| October 06, 2026 | -65.58M |
| October 05, 2026 | -65.58M |
| October 02, 2026 | -65.27M |
| October 01, 2026 | -64.34M |
| September 30, 2026 | -62.48M |
| September 29, 2026 | -62.48M |
| September 28, 2026 | -62.48M |
| September 25, 2026 | -62.48M |
| September 24, 2026 | -58.77M |
| September 23, 2026 | -59.70M |
| September 22, 2026 | -58.77M |
| September 21, 2026 | -60.63M |
| September 18, 2026 | -60.63M |
| September 17, 2026 | -59.39M |
| September 16, 2026 | -63.10M |
| September 15, 2026 | -60.01M |
| September 14, 2026 | -58.15M |
| September 11, 2026 | -56.91M |
| September 10, 2026 | -59.39M |
| September 09, 2026 | -58.15M |
| September 08, 2026 | -59.08M |
| September 04, 2026 | -57.53M |
| September 03, 2026 | -59.39M |
| Date | Value |
|---|---|
| September 02, 2026 | -57.53M |
| September 01, 2026 | -60.63M |
| August 31, 2026 | -61.25M |
| August 28, 2026 | -60.63M |
| August 27, 2026 | -58.15M |
| August 26, 2026 | -57.53M |
| August 25, 2026 | -55.67M |
| August 24, 2026 | -58.77M |
| August 21, 2026 | -57.84M |
| August 20, 2026 | -60.01M |
| August 19, 2026 | -56.91M |
| August 18, 2026 | -58.15M |
| August 17, 2026 | -61.25M |
| August 14, 2026 | -63.10M |
| August 13, 2026 | -62.48M |
| August 12, 2026 | -63.10M |
| August 11, 2026 | -65.58M |
| August 10, 2026 | -64.96M |
| August 07, 2026 | -64.34M |
| August 06, 2026 | -64.34M |
| August 05, 2026 | -64.34M |
| August 04, 2026 | -64.34M |
| August 03, 2026 | -64.96M |
| July 31, 2026 | -64.96M |
| July 30, 2026 | -63.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -43.38M |
| CorMedix, Inc. | 456.32M |
| Eloxx Pharmaceuticals, Inc. | -0.6934M |
| BioStem Technologies, Inc. | 41.31M |
| Wave Life Sciences, Inc. | 223.66M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.37M |
| Total Expenses (Quarterly) | 22.37M |
| EPS Diluted (Quarterly) | -0.3613 |
| Earnings Yield | -148.3% |
| Normalized Earnings Yield | -143.28 |